# US 2026/0062705 A1 · Treatment for ovarian cancer with oligonucleotides targeting fibroblast activation protein alpha

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062705 A1
- Document ID: US20260062705A1
- Status: Published application
- Kind: A1
- Application number: 19/106,799
- Filed: 2023-08-31
- Published: 2026-03-05
- Earliest claimed: 2022-08-31
- Applicants: University of Florida Research Foundation, Incorporated
- Inventors: Shuang HUANG; Bin LI
- Web page: https://patentgrep.com/patent/US20260062705A1

## CPC

- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/16: Aptamers
- C12N 2310/322: 2'-R Modification
- C12N 2310/3519: Fusion with another nucleic acid
- C12N 2310/531: Stem-loop; Hairpin
- C12Y 304/14005: Dipeptidyl-peptidase IV (3.4.14.5)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

Fibroblast activation protein a (FAP) is a tumor-specific protein and well characterized for its function in tumorigenicity. However, agents against its enzymatic activity or monoclonal antibodies against its cell surface presence are unsuccessful in clinic for uncharacterized reason. In this disclosure, provided is an anti-FAP siRNA and FAP-silencing oligonucleotides comprising anti-FAP siRNAs linked at both ends to aptamers recognizing cancer markers, in particular aptamers recognizing epithelial cell adhesion molecule (EpCAM).

## Claims

### Claim 1

A FAP silencing oligonucleotide comprising an anti-FAP siRNA comprising
(1) a sense oligonucleotide of SEQ ID NO:3 or a biologically active fragment or variant thereof, and
(2) an antisense oligonucleotide of SEQ ID NO:4 or a biologically active fragment or variant thereof,
wherein the sense oligonucleotide and antisense oligonucleotide comprise 2′-fluoro-deoxyguanosine or natural deoxyguanosine.

### Claim 2 (depends on 1)

The FAP silencing oligonucleotide comprising an anti-FAP siRNA according to claim 1, wherein the anti-FAP siRNA is linked at both ends to an aptamer that recognize cancer markers on the cancer cell surface, wherein the aptamer linked at both ends can be the same aptamer or different aptamer.

### Claim 3 (depends on 1, 2)

The FAP silencing oligonucleotide comprising an anti-FAP siRNA according to claim 1 or 2, wherein the aptamer is EpCAM recognizing aptamer.

### Claim 4 (depends on 3)

The FAP silencing oligonucleotide comprising an anti-FAP siRNA according to claim 3, wherein the EpCAM recognizing aptamer is SEQ ID NO:1 or SEQ ID NO:2.

### Claim 5 (depends on 4)

The FAP silencing oligonucleotide comprising an anti-FAP siRNA according to claim 4, wherein
(1) the sense oligonucleotide is SEQ ID NO:5 or a biologically active fragment or variant thereof, and
(2) the antisense oligonucleotide is SEQ ID NO:6 or a biologically active fragment or variant thereof.

### Claim 6 (depends on 4)

The FAP silencing oligonucleotide comprising an anti-FAP siRNA according to claim 4, wherein
(1) the sense oligonucleotide is SEQ ID NO:7 or a biologically active fragment or variant thereof, and
(2) the antisense oligonucleotide is SEQ ID NO:8 or a biologically active fragment or variant thereof.

### Claim 7 (depends on 4)

The FAP silencing oligonucleotide comprising an anti-FAP siRNA according to claim 4, wherein
(1) the sense oligonucleotide is SEQ ID NO:9 or a biologically active fragment or variant thereof, and
(2) the antisense oligonucleotide of SEQ ID NO:10 or a biologically active fragment or variant thereof.

### Claim 9 (depends on 4)

The FAP silencing oligonucleotide comprising an anti-FAP siRNA according to claim 4, wherein
(1) the sense oligonucleotide is SEQ ID NO:11 or a biologically active fragment or variant thereof, and
(2) the antisense oligonucleotide is SEQ ID NO:12 or a biologically active fragment or variant thereof.

### Claim 10 (depends on 1, 6, 7, 8, 9)

A pharmaceutical composition for the treatment of cancer susceptible to FAP silencing, comprising a pharmaceutically acceptable carrier and at least one of FAP silencing oligonucleotides according to any one of claims 1, 6-9 or combination thereof.

### Claim 11 (depends on 1, 6, 7, 8, 9)

A method for treating a cancer susceptible to FAP silencing in a subject in need, comprising administering a therapeutically effective amount of FAP silencing oligonucleotides of any one of claims 1, 6-9 or combination thereof.

### Claim 12 (depends on 11)

The method of claim 11, wherein the cancer is colon adenocarcinoma, esophagus adenocarcinoma, liver hepatocellular carcinoma, squamous cell carcinoma, pancreas adenocarcinoma, islet cell tumor, rectum adenocarcinoma, gastrointestinal stromal tumor, stomach adenocarcinoma, adrenal cortical carcinoma, follicular carcinoma, papillary carcinoma, breast cancer, ductal carcinoma, lobular carcinoma, melanoma, intraductal carcinoma, mucinous carcinoma, phyllodes tumor, ovarian cancer including ovarian adenocarcinoma, endometrium adenocarcinoma, granulose cell tumor, mucinous cystadenocarcinoma, cervix adenocarcinoma, vulva squamous cell carcinoma, basal cell carcinoma, prostate cancer, giant cell tumor of bone, bone osteosarcoma, larynx carcinoma, lung adenocarcinoma, kidney carcinoma, urinary bladder carcinoma, Wilm's tumor, uterine cancer, endometrial cancer and lymphoma.

### Claim 13 (depends on 12)

The method of claim 12, wherein the cancer is ovarian cancer.

### Claim 14 (depends on 11)

The method of claim 11, further comprising co-administering a therapeutically effective amount of an adjunct cancer therapeutic agent,
wherein the adjunct cancer therapeutic agent comprises an antitumor alkylating agent, antitumor antimetabolite, antitumor antibiotics, plant-derived antitumor agent, antitumor platinum complex, antitumor camptothecin derivative, antitumor tyrosine kinase inhibitor, monoclonal or polyclonal antibody, interferon, biological response modifier, hormonal anti-tumor agent, anti-tumor viral agent, angiogenesis inhibitor, differentiating agent, PI3K/mTOR/AKT inhibitor, cell cycle inhibitor, apoptosis inhibitor, hsp 90 inhibitor, tubulin inhibitor, DNA repair inhibitor, antiangiogenic agent, receptor tyrosine kinase inhibitor, topoisomerase inhibitor, taxane, agent targeting Her2, hormone antagonist, agent targeting a growth factor receptor, or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 11)

The method of claim 11, further comprising treating FAP silencing-susceptible cancer with at least one adjunct cancer therapy protocol selected from the group consisting of surgery, radiation therapy, chemotherapy, gene therapy, DNA therapy, adjuvant therapy, neoadjuvant therapy, viral therapy, RNA therapy, immunotherapy, and nanotherapy.
